

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/122525 A1

(51) International Patent Classification:

A61K 47/26 (2006.01) A61P 9/10 (2006.01)
A61K 47/64 (2017.01) A61K 38/08 (2019.01)
A61K 47/61 (2017.01) A61K 38/12 (2006.01)
C07K 7/52 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2024/058316

(22) International Filing Date:

04 December 2024 (04.12.2024)

Published:

- with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/605,662 04 December 2023 (04.12.2023) US
63/652,629 28 May 2024 (28.05.2024) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**
[US/GB]; Ritter House, P.O. Box 173, Road Town, Tortola,
VG1110 (VG).

(72) Inventors: **DERAMON, Edward**; Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **MARCIN, Lawrence R.**; Biohaven Pharma-
ceuticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc.,
215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MOLECULAR DEGRADERS OF ANTI- β_1 EC_{II} AUTO-ANTIBODIES

(57) Abstract: The disclosure describes compounds of Formula (I) and Formula (II), which in non-limiting aspects contain an asialo-glycoprotein receptor (ASGPR) binding moiety and an anti- β_1 AR binding moiety. Compounds of Formula (I) and Formula (II) are useful in preventing, treating and/or ameliorating heart failure in a subject when administered therapeutically effective amounts.

WO 2025/122525 A1